

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

P.T.O. Form 1473 (Rev. 09/2005)

OMB No. 0651-0009 (Exp. 02/28/2021)

**Trademark/Service Mark Application, Principal Register  
Handwritten Signature**

**To the Commissioner for Trademarks:**

**MARK:** DRUGOME (Standard Characters, see below )

# DRUGOME

The literal element of the mark consists of DRUGOME. The mark consists of standard characters, without claim to any particular font style, size, or color.

The applicant, Roivant Sciences GmbH, a gesellschaft mit beschränkter haftung (gmbh) legally organized under the laws of Switzerland, having an address of

Viaduktstrasse 8  
Basel 4051  
Switzerland

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 009: Computer software; computer software for providing, analyzing and generating reports; computer software for data processing; software, programs and systems for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and/or transmission of data, images and information; software, programs and systems for the conversion, analysis, processing, storage and transmission of artificial intelligence; computer software for database integration; computer software for creating searchable databases of information and data; software for analytics in the fields of healthcare, pharmaceuticals, biomedicine, pharmaceutical and biomedical research and development, and for clinical trial and post-market trial data; downloadable computer software featuring electronic computer databases of pharmaceuticals, biomedical research, and for clinical trial and post-market trial data; downloadable computer search engine software for compiling, accessing and providing updated scientific, medical, pharmaceutical and clinical information, and news information of general interest

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on Switzerland application number 80616/2018, filed 10/24/2018.

INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the submission of the foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.

Based on Foreign Registration: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services, and submits a copy of Switzerland registration number 728943, and/or proof of renewal, registered 03/27/2019 with a renewal date of \_\_\_\_\_ and an expiration date of 10/24/2028, and translation thereof, if appropriate.

[Foreign Registration-1](#) [reg-20671224226-

115717730\_.\_Swiss\_registration\_certificate\_for\_DRUGOME\_\_F3011118x96B9E\_.pdf ]

The foreign registration that is the basis of the U.S. application under §44(e) of the Trademark Act includes a claim of standard characters or the country of origin's standard character equivalent.

International Class 035: Advertising; business management; business administration; office functions; business research services; business information services; market research; provision of market research information; data processing services; analysis of business data; artificial intelligence and machine learning statistical analysis, consultancy and reporting for pharmaceutical and biomedical research; business analysis and statistical analysis of healthcare data, pharmaceuticals, biomedical research, and for clinical trial and post-market data; systematization and compilation of data in computer databases, in particular compilation of information into computer databases for research and analysis purposes in the field of healthcare, pharmaceuticals, biomedicine, pharmaceutical and biomedical research and development, clinical trials and post-market data; professional business analysis and consultancy and statistical analysis in the fields of healthcare, pharmaceuticals, biomedicine, clinical trials, epidemiological research, pharmacoepidemiological research, post-market trials and research evaluating epidemiological outcomes

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on Switzerland application number 80616/2018, filed 10/24/2018.

INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the submission of the foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.

Based on Foreign Registration: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services, and submits a copy of Switzerland registration number 728943, and/or proof of renewal, registered 03/27/2019 with a renewal date of \_\_\_\_\_ and an expiration date of 10/24/2028, and translation thereof, if appropriate.

[Foreign Registration-1](#) [reg-1-20671224226-

115717730\_.\_Swiss\_registration\_certificate\_for\_DRUGOME\_\_F3011118x96B9E\_.pdf ]

The foreign registration that is the basis of the U.S. application under §44(e) of the Trademark Act includes a claim of standard characters or the country of origin's standard character equivalent.

International Class 036: Financial analysis; financial consulting; financial valuations and forecasting; financial analysis, namely, compiling and analyzing statistics and data; financial analysis of investments in pharmaceutical and biomedical research and development, and clinical and post-market trials; financial evaluation, tracking, analysis, forecasting, consultancy, advisory and research services relating to healthcare, pharmaceuticals, biomedicine, pharmaceutical and biomedical research and development, and clinical and post-market trials

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in



commerce on or in connection with the identified goods/services and asserts a claim of priority based on Switzerland application number 80616/2018, filed 10/24/2018.

INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the submission of the foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.

Based on Foreign Registration: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services, and submits a copy of Switzerland registration number 728943, and/or proof of renewal, registered 03/27/2019 with a renewal date of \_\_\_\_\_ and an expiration date of 10/24/2028, and translation thereof, if appropriate.

[Foreign Registration-1](#) [reg-2-20671224226-

115717730\_.\_Swiss\_registration\_certificate\_for\_DRUGOME\_\_F3011118x96B9E\_.pdf ]

The foreign registration that is the basis of the U.S. application under §44(e) of the Trademark Act includes a claim of standard characters or the country of origin's standard character equivalent.

International Class 042: Scientific and technological services and research and design relating thereto; analysis of technical data by computers; pharmaceutical, biomedical, biological therapeutic research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical and biopharmaceutical research and development; providing scientific research information in the field of pharmaceuticals, biomedicine, clinical trials and post-market trials; cloud computing; providing temporary use of online non-downloadable computer software featuring electronic computer databases of pharmaceuticals, biomedicine, pharmaceutical and biopharmaceutical research and development, medical information, clinical trial and post-market trial data; providing temporary use of online non-downloadable computer software for research in the field of pharmaceuticals and biopharmaceuticals; providing temporary use of online non-downloadable computer software for compiling, accessing, controlling, managing and providing updated scientific, pharmaceutical, medical and clinical information, and news information of general interest; providing temporary use of non-downloadable software applications accessible via a web site for data analytics, financial analytics and risk management for use in the fields of pharmaceutical and biomedical research and development, clinical trials, and the provision of medical and healthcare services

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on Switzerland application number 80616/2018, filed 10/24/2018.

INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the submission of the foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.

Based on Foreign Registration: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services, and submits a copy of Switzerland registration number 728943, and/or proof of renewal, registered 03/27/2019 with a renewal date of \_\_\_\_\_ and an expiration date of 10/24/2028, and translation thereof, if appropriate.

[Foreign Registration-1](#) [reg-3-20671224226-

115717730\_.\_Swiss\_registration\_certificate\_for\_DRUGOME\_\_F3011118x96B9E\_.pdf ]

The foreign registration that is the basis of the U.S. application under §44(e) of the Trademark Act includes a claim of standard characters or the country of origin's standard character equivalent.

The applicant's current Attorney Information:

Allison Strickland Ricketts and Joyce M. Ferraro of Fross Zelnick Lehrman & Zissu, P.C. 4 Times  
Square, 17th Floor  
New York, New York 10036  
United States  
212-813-5900(phone)  
ricketts-docket@fzlj.com (authorized)

The attorney docket/reference number is ROIV 1905651.

The applicant's current Correspondence Information:

Allison Strickland Ricketts  
Fross Zelnick Lehrman & Zissu, P.C.  
4 Times Square, 17th Floor  
New York, New York 10036  
212-813-5900(phone)  
ricketts-docket@fzlj.com; ferraro-docket@fzlj.com (authorized)

**E-mail Authorization:** I authorize the USPTO to send e-mail correspondence concerning the application to the applicant, the applicant's attorney, or the applicant's domestic representative at the e-mail address provided in this application. I understand that a valid e-mail address must be maintained and that the applicant or the applicant's attorney must file the relevant subsequent application-related submissions via the Trademark Electronic Application System (TEAS). Failure to do so will result in the loss of TEAS Reduced Fee status and a requirement to submit an additional processing fee of \$125 per international class of goods/services.

A fee payment in the amount of \$1100 will be submitted with the application, representing payment for 4 class(es).



### Declaration

Read the following statements before signing. Acknowledge the statements by signing below.

• **Basis:**

**If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a):**

- The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered;
- The mark is in use in commerce on or in connection with the goods/services in the application;
- The specimen(s) shows the mark as used on or in connection with the goods/services in the application; and
- To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.

**And/Or**

**If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e):**

- The signatory believes that the applicant is entitled to use the mark in commerce;
  - The applicant has a bona fide intention to use the mark in commerce on or in connection with the goods/services in the application; and
  - To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
- To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
  - To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
  - The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

**Signature Section:**

**NOTE:** The same person may sign the declaration on behalf of the other joint applicant(s), by merely making identical entries. The USPTO will presume that the one person who has signed was, in fact, authorized to sign on behalf of the other person(s).

Signature: \_\_\_\_\_

Signatory's Name: \_\_\_\_\_

Signatory's Position: \_\_\_\_\_

Signatory's Phone Number: \_\_\_\_\_

Date Signed: \_\_\_\_\_

**NOTE TO APPLICANT:** When filed as part of the electronic form (i.e., scanned and attached as an image file), the signature page **must** include both the signature information **and** the declaration language. Do **not** include the entire application, but do ensure that the declaration language actually appears; *a signature by itself will not be acceptable*. If, due to browser limitations, the declaration language appears on a previous page when